Article Text


SDHB mutation analysis in familial and sporadic phaeochromocytoma identifies a novel mutation
  1. A Cascón,
  2. A Cebrián,
  3. S Ruiz-Llorente,
  4. D Tellería,
  5. J Benítez,
  6. M Robledo
  1. Department of Human Genetics, Spanish National Cancer Center (CNIO), Madrid, Spain
  1. Correspondence to:
 Dr A Cascón, Department of Human Genetics, Centro Nacional de Investigaciones Oncologicas, Melchor Fernandez Almagro 3, 28029 Madrid, Spain;

Statistics from

Phaeochromocytoma is a rare, neuroendocrine, chromaffin staining tumour that usually arises within the adrenal medulla, although extra-adrenal phaeochromocytomas also appear in ganglia of the sympathetic nervous system. Approximately 10% of phaeochromocytomas are hereditary1 and may be found in association with von Hippel-Lindau disease, multiple endocrine neoplasia type 2, or neurofibromatosis type 1.1–3 Familial paraganglioma (PGL) is a inherited disorder characterised by the development of highly vascular tumours in the head and neck. Recent studies have related the presence of mutations on structural (SDHC, SDHD) and catalytic (SDHB) succinate dehydrogenase subunits to familial and sporadic phaeochromocytoma and/or paraganglioma susceptibility. While the SDHD locus is maternally imprinted, SDHB has classical autosomal dominant inheritance. Since Baysal et al4 first described SDHD mutations as being associated with PGL, the screening of such alterations has become routine in the diagnosis of paraganglioma and phaeochromocytoma.5 Astuti et al6 reported the first known mutations in the SDHB gene that caused susceptibility to familial phaeochromocytoma alone and to familial phaeochromocytoma with head and neck paraganglioma. A recent study reported mutations in the SDHB gene in ∼20% cases of PGL and ∼3% of sporadic paragangliomas. With regard to SDHC, only one study has identified a germline SDHC mutation in all the affected members of a family as being the underlying cause of PGL3.8

To investigate further the involvement of SDHB and SDHC in paraganglioma and phaeochromocytoma susceptibility, we searched for germline mutations in 22 patients, 17 with phaeochromocytoma, three with paraganglioma, and two cases with both (table 1).

Table 1

Clinical and molecular data of patients analysed. SDHB and SDHC mutation analysis was performed in 22 consecutive, previously unselected patients with phaeochromocytoma and/or paraganglioma, aged 11 to 68 years, with or without a family history and from unrelated families who had tested negative for germline mutations in VHL, RET, and SDHD genes. Genomic DNA was extracted from the patients’ blood samples following standard methods. Informed consent was obtained from all patients


The patients, with or without a family history and without previous selection, had previously tested negative for VHL, RET, and SDHD mutations (in press). We used amplification analysis followed by sequencing of PCR products. Among the samples examined, we identified six heterozygous variants in the SDHB gene, one nonsense mutation (R27X), two silent mutations (L7L, A6A), and three intronic changes (IVS4+35ins, IVS2-33G/A, IVS2-35A/G). The SDHB mutation was a CGA→TGA (R27X) transition in exon 2 of case 22 (table 1). This R27X change gave rise to a 26 amino acid truncated protein by creating a premature stop codon (fig 1). The patient was a 32 year old male with familial phaeochromocytoma and several tumours derived from the sympathetic nervous system. He was diagnosed with adrenal phaeochromocytoma and para-aortic paraganglioma, both of which were surgically removed, carotid body paraganglioma, and deafness. The patient’s mother was diagnosed with hyperparathyroidism and two affected paternal first cousins were diagnosed with extra-adrenal phaeochromocytoma.

Figure 1

Sequencing chromatogram showing the alteration (denoted by arrowhead). Affected codon and amino acid are indicated below. The analysis was carried out by genomic DNA amplification of peripheral blood leucocytes. The primer pairs for exon amplification of exons 1 to 6 of the SDHC gene were designed on the basis of its genomic sequence (accession number AH006319) and were as follows (numbers in brackets indicate the amplicon sizes): 1F (5′-CAC ATG ACA CCC CCA ACC-3′), 1R (5′-CTC CCA GTC CCA CTG AAG TC-3′) (138 bp), 2F (5′-TCT ATC CCT TCA CCC CTA AAA A-3′), 2R (5′-AGC GAG ACT CCG TCT CAA AA-3′) (205 bp), 3F (5′-GAT TAC AGG CCT GAG CAA CC-3′), 3R (5′-CTG GCT CCA GAA TCC TTC CT-3′) (251 bp), 4F (5′-TTC CTT TTT AAA ATT GTC TTT GTG TG-3′), 4R (5′-TTC AAA GGA GGC GGA GAC TA-3′) (185 bp), 5F (5′-CAG GGG TCC CAG TTT TAT GT-3′), 5R (5′-AGA AAA TGT GCA AAT CCC GA-3′) (271 bp), 6F (5′-CGC TTT TCT CTA GAA TCA TGC TG-3′), 6R (5′-AAG ATG ATG CTG GGA GCC T-3′) (257 bp). The primer pairs for exon amplification of exons 1 to 8 of the SDHB gene (accession number U17248) were as follows: 1F (5′-CTC CCA CTT GGT TGC TCG -3′), 1R (5′-GGC TTT CCT GAC TTT TCC CT-3′) (244 bp), 2F (5′-GCG TTA CAT CTG TTG TGC CA-3′), 2R (5′-TTA AGC CTC CCA AGG ATG TG-3′) (300 bp), 3F (5′-ACA TCC AGG TGT CTC CGA TT-3′), 3R (5′-AGC CCA ACA GGA ATG AAA TG-3′) (197 bp), 4F (5′-CAG CAA GGA GGA TCC AGA AG-3′), 4R (5′-CCC CCA TGC AAA TAA AAA CA-3′) (270 bp), 5F (5′-AAA GCT GAG GTG ATG ATG GAA-3′), 5R (5′-AGC TTA TGT TCC CTG CCA AG-3′) (272 bp), 6F (5′-GTC TCT CCC GTC ACA AGC TC-3′), 6R (5′-CCT CTT GGA CTT CTG GAT GC-3′) (209 bp), 7F (5′-GCA GCT CAG CTA ATC ATC CC-3′), 7R (5′-ACT TCT GGC GTG TCA GCT CT-3’) (208 bp), 8F (5′-TGA ACC AGC TGA GGA AGG AG-3′), 8R (5′-TGC TGT ATT CAT GGA AAA CCA A-3′) (275 bp).

Allele frequencies of the polymorphisms were determined by SSCP or CSGE of 200 chromosomes from a control population (table 1) and IVS4+35ins was not found. Nevertheless, it was not possible to ascribe any deleterious function to this unknown variant because RNA from the patient was not available. IVS2-33G/A and IVS2-35A/G, respectively, had frequencies of 3.3% and 7.2% in controls; no doubly heterozygous subjects were present.


Analysing the genotypic distribution of both polymorphisms in our small series of patients, we found a higher proportion of IVS2-33G/A heterozygotes among patients. This implies that this polymorphism could be acting as a low penetrance allele in the development of the disease (odds ratio=3.5, 95% CI 1.04 to 11.79). Broader case control studies are necessary in order to examine the role of this change in the pathogenicity of these tumour types.

No mutations in the SDHC gene were found in any of the 22 families tested. These results are consistent with those of other studies, which found no SDHC mutations in eight families or in 24 unrelated patients6 or in 19 unrelated PGL families.9 However, in another study, the discovery of several intronic polymorphisms led to the identification of large genomic deletions spanning the SDHC gene in two unrelated PGL3 families, and to the conclusion that this kind of recurrent deletion was the likely cause of PGL3.10 Our study confirmed that the contribution of point mutations of the SDHC gene to the susceptibility to developing neuroendocrine tumours remains unclear and suggested that screening for SDHC point mutations may not be a sensitive approach to the determination of predisposition to paraganglioma or phaeochromocytoma. A study of gross deletions remains to be carried out.

Key points

  • Phaeochromocytoma is a neuroendocrine tumour that usually arises from chromaffin cells localised within the adrenal medulla, although ∼15% of the lesions are found extra-adrenally. These tumours, which produce and secrete catecholamines, are mainly sporadic, but about 10% are hereditary and often associated with germline mutations in the VHL, RET, and NF1 genes and also in the SDHD and SDHB genes.

  • Hereditary paraganglioma is a rare inherited disorder characterised by the development of benign extra-adrenal tumours in the head and neck, and which is also associated with SDHB, SDHD, and SDHC mutations.

  • These genes encode the catalytic and the two structural subunits of succinate dehydrogenase complex II and although the involvement of SDHD in neuroendocrine tumour susceptibility is well known, there is less evidence of any contribution by SDHB and SDHC.

  • We report here the analysis of the SDHB and SDHC genes in the search for germline mutations in patients from unrelated index cases with phaeochromocytoma and/or paraganglioma disorders and with or without a family history. The patients had previously tested negative for germline mutations in VHL, RET, and SDHD and had not been previously selected. We found one previously unreported nonsense SDHB mutation in one case of familial phaeochromocytoma (R27X), two silent mutations (L7L, A6A), and three intronic substitutions (IVS4+35ins, IVS2-33G/A, IVS2-35A/G) in SDHB. We did not find any germline mutations in SDHC.

  • This study provides evidence supporting the recommendation of the use of the SDHB gene in genetic screening for phaeochromocytoma and paraganglioma.

Thus, in addition to the SDHB mutation previously described by Astuti et al6 in eight patients with familial phaeochromocytoma and/or familial paraganglioma susceptibility, here we report a novel SDHB germline mutation found in a Spanish patient with familial phaeochromocytoma that resulted in the loss of this catalytic subunit. The presence of this unrelated mutation is consistent with the idea of there having been no founder mutations in SDHB, since seven different mutations have been described in this gene.7 We also note the importance of SDHB mutations in familial versus sporadic cases, since no germline mutations were found in this study in sporadic cases and only 3-4% of subjects tested in other reports had such alterations.6,7

The SDHB gene maps to chromosome band 1p35-36.1, a region of frequent allele loss in several endocrine tumours, such as phaeochromocytomas, parathyroid adenomas, medullary thyroid carcinomas, and anterior pituitary adenomas.11–13 and encodes the iron sulphur protein (Ip) of succinate dehydrogenase, a mitochondrial enzyme. Germline mutations in the SDHB gene and in the other succinate dehydrogenase subunits, SDHD and SDHC, have recently been postulated as being associated with hereditary and non-familial paraganglioma or phaeochromocytoma.4–8 Its involvement in other tumour types, such as primary nasopharyngeal carcinoma, is currently under study.14 We can conclude from this study that the participation of the Ip subunit in the development of susceptibility to familial phaeochromocytoma is reconfirmed by another familial case with a germline mutation. Despite the evident association of this mitochondrial enzyme defect with tumorigenesis, as yet there is no convincing explanation for such a relation between mitochondrial dysfunction and development of neuroendocrine tumours. Otherwise, our results support the recommendation of conducting SDHB germline mutation searches in routine genetic screening of kindreds that test negative for germline mutations in other genes associated with these pathologies, such as RET, VHL, or even SDHD.


We thank the patients participating in this study and the clinicians who provided blood samples and clinical information. We are also grateful for the technical assistance of Rocío Letón. This work was partially supported by the Fondo de Investigaciones Sanitarias project, FIS 00/0118. Alberto Cascon is a postdoctoral fellow of the Excmo Ayuntamiento de Madrid, Spain.


View Abstract

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.